Cancer and Genetics: Part I

Martha Weinar

Kathleen Calzone

Bridget Le Grazie

ONF 2003, 30(6), 921-922. DOI: 10.1188/03.ONF.921-922

Jump to a section


    Baty, B.J., Kinney, A.Y., & Ellis, S.M. (2003). Developing culturally sensitive cancer genetics communication aids for African Americans. American Journal of Medical Genetics, 118A, 146-155.

    Burhansstipanov, L., Bemis, L.T., & Dignan, M.B. (2001). Native American cancer education: Genetic and cultural issues. Journal of Cancer Education, 16, 142-145.

    Glanz, K., Grove, J., Lerman, C., Gotay, C., & Le Marchand, L. (1999). Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiology, Biomarkers and Prevention, 8, 329-336.

    Lehmann, L.S., Weeks, J.C., Klar, N., & Garber, J.E. (2002). A population-based study of Ashkenazi Jewish women's attitude toward genetic discrimination and BRCA1/2 testing. Genetics Medicine, 4, 346-352.

    Lerman, C., Hughes, C., Benkendorf, J.L., Biesecker, B., Kerner, J., Willison, J., et al. (1999). Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiology, Biomarkers and Prevention, 8, 361-367.

    Lewis, L.J. (2002). Models of genetic counseling and their effects on multicultural genetic counseling. Journal of Genetic Counselors, 11, 193-212.

    Meiser, B., Eisenbruch, M., Barlow-Stewart, K., Tucker, K., Steel, Z., & Goldstein, D. (2001). Cultural aspects of cancer genetics: Setting a research agenda. Journal of Medical Genetics, 38, 425-429.

    Olopade, O.I., Fackenthal, J.D., Dunston, G., Tainsky, M.A., Collins, F., & Whitfeld-Broome, C. (2003). Breast cancer genetics in African Americans. Cancer, 97(1 Suppl.), 236-245.

    Schwartz, M.D., Benkendorf, J., Lerman, C., Isaac, C., Ryan-Robertson, A., & Johnson, L. (2001). Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/2: Testing among Ashkenazi Jewish women. Cancer, 92, 932-940.

    American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397-2406.

    Burke, W., Pinsky, L.E., & Press, N.A. (2001). Categorizing genetic tests to identify their ethical, legal, and social implications. American Journal of Medical Genetics, 106, 233-240.

    Calzone, K., Jenkins, J., & Masny, A. (2002). Core competencies in cancer genetics for advanced practice nurses. Oncology Nursing Forum, 29, 1327-1333.

    Cassells, J.M., Jenkins, J., Lea, D.H., Calzone, K., & Johnson, E. (2003). An ethical assessment framework for addressing global genetic issues in clinical practice. Oncology Nursing Forum, 30, 383-390.

    Frank-Stromborg, M., & Ganschow, J.R. (2002). Legal issues in the early detection and monitoring of cancer. Seminars in Oncology Nursing, 18, 128-134.

    Geller, G., Botkin, J., Green, M., Press, N., Biesecker, B., Wilfond, B., et al. (1997). Genetic testing for susceptibility to adult-onset cancer: The process and content of informed consent. JAMA, 277, 1467-1474.

    Hall, M.A., & Rich, S.S. (1999). Laws restricting health insurers' use of genetic information: Impact on genetic discrimination. American Journal of Human Genetics, 66, 293-307.

    Hall, M.A., & Rich, S.S. (2000). Patients' fear of genetic discrimination by health insurers: The impact of legal protections. Genetics in Medicine, 2, 214-221.

    International Society of Nursing in Genetics, Inc. (1998). Statement on the scope and standards of genetic clinical nursing practice. Washington, DC: American Nurses Publishing.

    Lawrence, W.F., Peshkin, B.N., Liang, W., Isaacs, C., Lerman, C., & Mandelblatt, J.S. (2001). Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiology, Biomarkers and Prevention, 10, 475-481.

    Oncology Nursing Society. (2002). Cancer predisposition genetic testing and risk assessment counseling [Position statement]. Pittsburgh, PA: Author.

    Rieger, P.T., & Pentz, R.D. (1999). Genetic testing and informed consent. Seminars in Oncology Nursing, 15, 104-115.

    Surbone, A. (2001). Ethical implications of genetic testing for breast cancer susceptibility. Critical Reviews in Oncology/Hematology, 40, 149-157.

    Williams, J.K., & Lea, D.H. (1995). Applying new genetic technologies: Assessment and ethical considerations. Nurse Practitioner, 20(7), 21-26.

    Anzick, S.L., & Trent, J.M. (2002). Role of genomics in identifying new targets for cancer therapy. Oncology, 16(5 Suppl. 4), 7-13.

    Danzon, P., & Towse, A. (2002). The economics of gene therapy and of pharmacogenetics. Value in Health, 5(1), 5-13.

    Hutchinson, E. (2001). Working towards tailored therapy for cancer. Lancet, 357, 1508-1510.

    Innocenti, F., & Ratain, M.J. (2002). Update on pharmacogenetics in cancer chemotherapy. European Journal of Cancer, 38, 639-644.

    Loni, L., Del Tacca, M., & Danesi, R. (2001). Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. British Journal of Cancer, 85, 1425-1431.

    Nagasubramanian, R., Innocenti, F., & Ratain, M.J. (2003). Pharmacogenetics in cancer treatment. Annual Review of Medicine, 54, 437-452.

    Raghavan, D. (2003). Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer, 97(8 Suppl.), 2083-2089.

    Relling, M.V., & Dervieux, T. (2001). Pharmacogenetics and cancer therapy. National Review of Cancer, 2, 99-108.

    Seufferlein, T., & Boehm, B.O. (2002). The impact of pharmacogenomics on gastrointestinal cancer therapy. Pharmacogenomics, 3, 625-633.

    Tsongalis, G.J., Cartun, R.W., & Ricci, A. (2000). Gene amplification as means for determining therapeutic strategies in human cancers. Clinical Chemistry and Laboratory Medicine, 38, 837-839.

    Walters, J.W., & McLeod, H.L. (2003). Cancer pharmacogenetics: Current and future applications. Biochimica et Biophysica Acta, 1603, 99-111.

    Workman, P. (2002). The impact of genomic and proteomic technologies on the development of new cancer drugs. Annals of Oncology, 13(Suppl. 4), 115-124.

    Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiology, Biomarkers and Prevention, 9, 1251-1254.

    Biesecker, B.B., Ishibe, N., Hadley, D.W., Giambarresi, T.R., Kase, R.G., Lerman, C., et al. (2000). Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. American Journal of Medical Genetics, 93, 257-263.

    Bonadona, V., Saltel, P., Desseigne, F., Mignotte, H., Saurin, J.C., Wang, Q., et al. (2002). Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: Reactions and behavior after the disclosure of a positive test result. Cancer Epidemiology, Biomarkers and Prevention, 11, 97-104.

    Broadstock, M., Michie, S., & Marteau, T. (2000). Psychological consequences of predictive genetic testing: A systemic review. European Journal of Human Genetics, 8, 731-738.

    Codori, A.M., Zawacki., K.L., Petersen, G.M., & Giardiello, F.M. (2003) Genetic testing for hereditary colorectal cancer in children: Long-term psychological effects. American Journal of Medical Genetics, 116A, 117-128.

    Coyne, J., Kruus, L., Racioppo, M., Calzone, K., & Armstrong, K. (2003). What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? American Journal of Medical Genetics, 116A, 222-228.

    Dorval, M., Patenaude, A., Schneider, K., Kieffer, S., DiGianni, L., Kalkbrenner, K., et al. (2000). Anticipated versus actual emotional reactions to disclosure of cancer genetic test results: Findings from p53 and BRCA1 testing programs. Journal of Clinical Oncology, 18, 2135-2142.

    Freyer, G., Dazord, A., Schlumberger, M., Conte-Devolx, B., Ligneau, B., Trillet-Lenoir, V., et al. (1999). Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: A multicentric pilot-evaluation. Annals of Oncology, 10, 87-95.

    Grosfeld, F.J., Lips, C.J., Beemer, F.A., Blijham, G.H., Quirijnen, J.M., Mastenbroek, M.P., et al. (2000). Distress in MEN 2 family members and partners prior to DNA test disclosure. Multiple endocrine neoplasia type 2. American Journal of Medical Genetics, 91, 1-7.

    Johnson, K.A., Rosenblum-Vos, L., Petersen, G.M., Brensinger, J.D., Giardiello, F.M., & Griffin, C.A. (2000). Response to genetic counseling and testing for the APC 11307K mutation. American Journal of Medical Genetics, 91, 207-211.

    Jordan, J., Evans, G., Evers-Kiebooms, G., Julian-Reynier, C., Kash, K., & Watson, M. (2002). Congress report of the Seventh International Meeting on Psychosocial Aspects of Genetic Testing for Hereditary Breast and/or Ovarian Cancer (HBOC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC). Psycho-Oncology, 11, 536-539.

    Lerman, C., Croyle, R.T., Tercyak, K.P., & Hamann, H. (2002). Genetic testing: Psychosocial aspects and implications. Journal of Consulting and Clinical Psychology, 70, 784-797.

    Lerman, C., Hughes, C., Trock, B.J., Myers, R.E., Main, D., Bonney, A., et al. (1999). Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA, 281, 1618-1622.

    Pasacreta, J., Jacobs, L., & Cataldo, J. (2002). Genetic testing for breast and ovarian cancer risk: The psychosocial issues. American Journal of Nursing, 102, 40-47.

    Tercyak, K.P., Peshkin, B.N., Streisand, R., & Lerman, C. (2001). Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psycho-Oncology, 10, 336-346.